NCT00998699View on ClinicalTrials.gov

Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Type 1 Diabetes
Interventions
DRUG

Xoma 052

Sterile solution subcutaneously administered every 4 weeks for 12 weeks

DRUG

Placebo

Sterile solution subcutaneously administered every 4 weeks for 12 weeks

Trial Locations (2)

Unknown

Basel

Zurich

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

XOMA (US) LLC

INDUSTRY